Overall, these findings suggest that the down‐regulation of Cyp2c29 expression by DDX17 and the subsequent low EET levels may trigger lipid metabolism dysfunction and anti‐inflammatory effects and may be a critical pathological consequence of NASH in vivo. This evidence concerns the gene DDX17 and metabolic dysfunction-associated steatohepatitis.